All problems
pharma
You need senior UK commercial leadership but not a full hire
"We needed someone who could walk into an ICB meeting and know how the room worked. We couldn't justify a full-time hire at this stage, but the gap was costing us months."
Takes two minutes. A free, no-obligation chat with Solva.
- A six-month delay in establishing UK commercial leadership during a launch window costs an estimated equivalent of four to six months of peak quarterly revenue
- Fractional commercial directors in UK pharma typically cost 40 to 60% less than a full-time equivalent at director level
- Companies that engage fractional UK commercial leadership at pre-launch report faster time-to-formulary and stronger year-one uptake
- Delayed formulary and access conversations cost months of prescribing revenue
- Competitors with local leadership establish relationships first
- Board loses confidence in UK commercial execution
- Field team operates without strategic direction
- Patient access is deferred
Frequently asked questions
Why does this problem persist?
The UK market requires relationships that take years to build A full-time hire cannot be justified at pre- or early-commercial stage Interim or fractional models are underused in UK pharma
What is the cost of leaving it unaddressed?
Each month without senior UK commercial leadership during a launch window costs an estimated fraction of monthly peak revenue potential.
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.